Non-small-cell lung carcinoma (NSCLC) describes a histologically heterogeneous group of tumours with variable clinical behaviour. Performance status, tumour stage and histological type have important prognostic implications, but clinical outcomes in individual patients remain unpredictable. A significant minority of NSCLCs (10%-30%) show neuroendocrine (NE) differentiation, and a number of studies have attempted to evaluate the therapeutic and prognostic significance of the expression of NE markers on the basis of the theoretical assumption that NE-differentiated tumours may be associated with an adverse prognosis and greater chemosensitivity. However, the results of these studies are conflicting: some have found that NE differentiation has a negative impact on survival, but
Introduction
Lung cancer is the leading cause of cancer-induced deaths in the world and has a very poor prognosis. Despite recent therapeutic advances, the overall fiveyear survival rate has improved little over the past thirty years and remains a dismal 14%.
Lung tumours are classified into two major histological subtypes that have different morphological, biological and clinical properties: neuroendocrine (NE) carcinomas, which include a spectrum of increasingly aggressive tumours from carcinoids to small cell carcinomas (SCLC), and non-small-cell lung carcinomas (NSCLC), which form a group of histologically heterogeneous and clinically variable tumours, including squamous cell carcinoma, adenocarcinoma and large cell carcinoma. Performance status, tumor stage and histological type all have important prognostic implications, but the clinical outcome in an individual patient remains unpredictable.
The biological differences between SCLC and NSCLC are well known. Classical SCLC is a chemo-and radiosensitive tumour that is immunohistochemically characterised by the expression of various hormones, neuropeptides and specific cell surface markers. However, it has also been found that a significant minority (10%-30%) of NSCLCs may also express NE features [1] .
Senden et al. investigated the value of various NE markers in a series of 88 bronchopulmonary neoplasms: 52 squamous cell carcinomas, 18 adenocarcinomas, eight SCLCs, five carcinoids and five atypical carcinoids [2] . NE-specific proteins were expressed in most of the carcinoids and SCLCs, and their expression correlated with neural cell adhesion molecules (NCAMs) and synaptophysin (Syn); 28 of the 52 squamous cell carcinomas also showed NE features. The most important observation was that the limited correlation between the expression of the different NE markers and the percentage of tumours expressing NE features greatly depends on the marker used. These data suggest that the expression of an individual NE marker is not an absolute criterion for identifying NE differentiation (Table 1) .
In addition to being an interesting finding concerning the histogenesis and biological behaviour of NSCLCs, there is also supportive evidence that NE features may have clinical significance. Over the last few years, a number of studies have been undertaken to evaluate the therapeutic and prognostic significance of the NE phenotype in NSCLCs, on the theoretical grounds that the tumours showing NE differentiation may be associated with an adverse prognosis and greater chemosensitivity. However, the data are conflicting. The frequency of NE differentiation is similar for all histologic tumour types, although some series have shown that adenocarcinomas We here review the results of the major studies of NE differentiation in NSCLCs in an attempt to elucidate its possible impact on clinical outcome.
NE differentiation and survival
In the search for factors that may predict outcome in patients with resected NSCLCs, a number of immunohistochemical markers of NE differentiation have been evaluated.
In 1989, Berendsen et al. [3] prospectively analysed 141 cases (70 stage I-II; 71 stage III) in terms of the reactivity of monoclonal antibody MOC-1, which is directed against the highly indicative NCAM marker of NE differentiation. Its presence was detected in 31% of the cases, and more frequently in adenocarcinomas. The biopsies containing more than 50% positive-staining tumour cells were recognised as being negative prognostic factors having a negative impact on survival. Similarly, Kibbelaar et al. investigated the expression of NCAM using a panel of monoclonal antibodies (Mab) that recognise different NCAM epitopes [4] . The NSCLCs that were positive for Mab 123C3 led to significantly shorter post-operative overall and disease-free survival than the 123C3-negative tumours.
Sundaresan et al. [5] evaluated the role of NE differentiation in both retrospective (n -315) and prospective (n = 44) cohorts of surgically treated NSCLC patients using chromogranin A (CgA), neurone-specific enolase (NSE), Syn, creatine kinase-BB, bombesin and neurotensin. The expression of two or more markers observed in 30% of cases correlated with a higher disease stage but not with survival.
These data are in contrast with the results of some recent trials that have failed to demonstrate any correlation between NE differentiation and prognosis in surgically treated patients. Linnoila et al. analysed surgical specimens of 237 NSCLCs obtained from previously studied Lung Cancer Study Group patients with detailed clinical follow-up [6] . The expression of four NE markers (NSE, CgA, Leu-7 and gastrin-releasing peptide) was detected by immunohistochemistry and histochemistry. Forty-six percent of the NSCLCs had at least one positive NE marker, but only 12% were positive for two or more. The measures of NE differentiation were not prognostic for recurrence or survival in surgically treated NSCLC patients. Between 1983 and 1995, the reactivity of Mab 123C3 was tested in 889 patients undergoing pulmonary resection in San Antonius Hospital in Nieuwegein,The Netherlands [7] . Only 128 tumours (14%) showed positive 123C3 staining, and there were no significant differences in terms of histotype, stage, and five-year survival between the patients with NCAMpositive or NCAM-negative tumours. The presence of NE differentiation demonstrated by NCAM expression, therefore, does not seem to alter prognosis significantly. However, since these studies only considered candidates for resection, most of the patients with clinical stage III and IV were excluded and, although it is unlikely that this had a significant impact on the reported results, the possibility of selection bias cannot be excluded.
Graziano et al. evaluated the expression of NSE, CgA, Leu-7, and Syn in 260 patients with surgically resected stage I-II NSCLC [8] . NSE was positive in 70%, CgA in 14%, Leu-7 in 8% and Syn in 11% of the cases. Sixty-one patients (24%) were positive for two or more NE markers. There was no significant difference in stage, site of relapse, and disease-free or overall survival of the patients with a single marker or those with two or more, and so NE differentiation had no prognostic significance. These data are supported by the findings of a retrospective study carried out by Kwa et al. [9] , who investigated the expression of NE differentiation markers (Syn, CgA, NCAM) in selected tumour samples from 19 patients with a post-operative disease-free survival of at least five years, and 20 patients who died within two years of resection. None of the markers distinguished the long and short-term survivors.
NE differentiation and response to chemotherapy
A number of studies have suggested that NSCLC patients with NE characteristics may be differently responsive to chemotherapy [10] . The identification of a subset of patients who may be more responsive to chemotherapy has important implications, particularly as more effective cisplatin-based regimens are developed. NE markers could help to select chemotherapy-responsive patients with metastatic disease or identify those with early stage disease who may benefit from adjuvant chemotherapy.
Skov et al. evaluated the prognostic impact of the histologic demonstration of CgA and NSE in 114 in- Abbreviations: NE -neuroendocrine; S -surgery; MAB -monoclonal antibody; NSE -neurone-specific enolase; CgA -chromogranin A; Syn -synaptophysin; NCAM -neural cell adhesion molecule; GRP -gastrin-releasing peptide; CT -chemotherapy, PGP; RT-PCR -reverse transciptase polymerase chain reaction. operable patients with pulmonary adenocarcinoma, all of whom received chemotherapy [11] . Eighteen patients (16%) had tumours with more than 10% anti-NSE stained cells, and 22 (19%) had more than 10% antiCgA stained cells. Forty-four percent of the NSEpositive patients responded to chemotherapy as against only 17% of the NSE-negative patients; the corresponding values for CgA were 30% and 19%. However, the survival curves of the NSE-and CgA-positive patients were not significantly different.
The impact of various biological and clinical characteristics on response rates and survival was evaluated in 97 advanced NSCLC patients by Carles et al. [12] , who analysed NSE, Syn, CgA and Leu-7 using immunohistochemical methods. A correlation between NE differentiation and a better response to chemotherapy was observed, but there was no evidence of longer survival in the NE-positive patients. The Cancer and Leukemia Group B studied patients with mediastinoscopically assessed stage IIIA NSCLCs, who received initial chemotherapy followed by surgery and post-operative chemotherapy and radiotherapy [13] . The pre-and postchemotherapy specimens from the 38 evaluable patients were compared in order to identify any differences in NE features and test whether this may be predictive of treatment response. The panel of NE markers included NSE, Leu-7, CgA and Syn. The results showed that the post-chemotherapy specimens had a higher percentage of NE-positive cells, but there was no correlation between the response to chemotherapy and the presence of the markers, and their expression did not identify a subgroup of stage IIIA NSCLC patients with a different prognosis. The reasons for this are unclear, but it may be that the markers did not reliably identify a chemotherapy-sensitive population and that other biological characteristics, such as HER-2, p53 or MDR, should be considered in denning chemoresistance. Schleusener et al. evaluated the expression of NE features in 107 patients with stage III and IV NSCLC treated with cisplatin and etoposide in order to determine the relationship between NE differentiation and chemotherapeutic response, disease progression and survival [14] . All of the patients were enrolled in North Central Cancer Treatment Group and Mayo Clinic protocols, and most had adenocarcinomas. Paraffin sections were stained for a panel of NE markers including CgA, Leu-7 and Syn. A response to chemotherapy was seen in 32% of the patients. Thirtyfive percent of the cases were immunoreactive to at least one marker, whereas only 11% were positive for two or more. The presence of NE differentiation significantly correlated with survival, being 249 days in the patients with NE-negative tumours, 311 days in those with tumours positive for one NE marker, and 464 days in those with tumours positive for two or more markers. Otherwise, there was no correlation between the presence of NE features and the response to chemotherapy, time to progression, disease stage or tumor grade.
Conclusion
The data described above are conflicting in terms of the therapeutic and prognostic significance of NE differentiation in NSCLC. Although several studies have suggested that the presence of NE markers in patients with advanced tumours may correlate with better response to chemotherapy [10, 11] and worse survival [3, 4] , other studies have found different and sometimes opposite results [7, 13, 14] ,
The interpretation of any individual study is burdened by technical and conceptual problems. First of all, most were retrospective, used different markers, and enrolled an insufficient number of patients to detect clinically meaningful differences. Moreover, there is no gold standard in defining NE differentiation, as is shown by the fact that the proportion of NE-positive NSCLCs varies according to the technique and marker used. Some authors have proposed the use of a panel of antibodies, with only the neoplasms that are positive for two or more reagents being considered as having NE features; but the antibodies making up the panel are different in different reports [2] . Furthermore, many immunohistochemically positive NSCLCs only stain focally because the sparseness of neurosecretory granules, innate tumour heterogeneity and the low level of neurosecretory granule content in poorly differentiated tumours limit the sensitivity of these highly specific markers.
Among the most widely used immunohistochemical reagents, CgA and Syn show the best correlation with ultrastructural evidence of NE differentiation. NSE has been found in other than neural and NE tissues, and its use should be avoided because of its lack of specificity [2] .
Reverse transcriptase-polymerase chain reaction (RT-PCR) may be a more sensitive method of detecting NE, but the role of this approach is still unclear. Abbona et al. have recently investigated the presence of CgA in 40 NSCLC patients using various techniques including immunohistochemistry and RT-PCR [15] . CgA mRNA was found by means of RT-PCR in 20 cases (50%), whereas only five tumours (13%) were immunohistochemically positive for the same marker. A statistically significant association was found between the two methods (P < 0.05), but the authors could not exclude the possibility that the presence of bronchial NE cells entrapped in the tumours may have accounted for some of the observed discrepancies.
In conclusion, the identification of subgroups of NSCLC patients with a different prognosis and response to chemotherapy remains an important goal. The clinical significance of NE differentiation is still unclear and the present markers may not adequately identify the key features of the NE phenotypes that correlate with better chemosensitivity or a worse prognosis. The identification of other biological characteristics could be used to differentiate NE neoplasms with different clinical behaviour because it is well known that SCLC is a chemosensitive NE malignancy, whereas bronchial carcinoid (another pulmonary malignancy with NE features) is relatively resistant. It is therefore necessary to be cautious when interpreting the various studies that have questioned the clinical impact of NE features in NSCLC. Further research is needed to see whether NE markers facilitate the selection of patients by predicting their response to chemotherapy and survival.
